搜索
产品
社区
市场
新闻
经纪商
更多
CN
开始
Insulet Corporation
做多
2022年12月1日
Two healthcare leaders, which one is best to own?
1
获取这个图表
获取这个图表
PODD
&
DXCM
are leading the sectors recovery.
Both are in the Medical Products Industry for diabetes.
Insulent (PODD) normally outperforms DexCom (DXCM) during and after a correction. Then, when they are in sustained uptrends, DXCM outperforms.
For the recent correction, PODD has a -45% deep base while DXCM has a -58%.
PODD bottmed 4 weeks before DXCM, but DXCM has rallied +74% and PODD +65% since.
So, it really depends on your strategy. If you are looking for aplha then
DXCM
is the stock for you but, if you prefer low beta then
PODD
is better.
Remember that aplha plays in both ways!
Which are you trading?
I'll trade the first that makes a new high.
dpuleo19
关注
更多:
Chart Patterns
diabetes
DXCM
healthcare
Technical Indicators
PODD
Trend Analysis
dpuleo19
关注
更多:
免责声明
这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在
使用条款
阅读更多信息。